Price
No data yet.
Social Signal Score
Revenue
$72.79M+23764.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael A. Metzger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 298
- Beta
- 0.37
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.86
Financials
Revenue
$72.79M+23764.9%Net Income
$-49.36MEBITDA
$-36.69MFree Cash Flow
$-30.31MEPS (diluted)
$-0.55Shares Outstanding (diluted)
88.99M+397.2%Operating Expenses
$109.58MCash & Debt
$547.86MRevenue by Segment (annual)
$172.35MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $172.35M | $-285.42M | $-3.29 |
| 2024 | $23.68M | $-318.76M | $-3.73 |
| 2023 | $0.00 | $-209.36M | $-2.98 |
| 2022 | $0.00 | $-149.34M | $-2.46 |
| 2021 | $139.71M | $24.93M | $0.48 |
| 2020 | $1.52M | $-73.07M | $-1.77 |
| 2019 | $1.52M | $-55.95M | $-1.84 |
| 2018 | $1.52M | $-73.96M | $-2.92 |
| 2017 | $2.11M | $-60.80M | $-2.90 |
| 2016 | $1.22M | $-44.47M | $-3.04 |
| 2015 | $627.0K | $-24.12M | $-4.31 |
| 2014 | $0.00 | $-19.83M | $-2.07 |
| 2013 | $0.00 | $-14.17M | $-1.77 |
| 2012 | $0.00 | $-9.96M | $-0.14 |
Valuation
SNDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Neutral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, wit…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Syndax Announces Participation in September Investor Conferences NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
View source ↗
Earnings
Mon, Nov 2(in 8 weeks)
Consensus estimate $-0.51 per share
Typical surprise +5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.55 vs $-0.45miss
- Thu, Apr 30$-0.48 vs $-0.59beat
- Thu, Feb 26$-0.78 vs $-0.58miss
- Mon, Nov 3$-0.70 vs $-0.74beat
- Mon, Aug 4$-0.83 vs $-1.00beat
- Mon, May 5$-0.98 vs $-1.04beat
Estimates and results for SNDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SNDX officers and directors.
- Bought
- $267k
- Sold
- $8.4m
5 trades
21 trades
- Metzger Michael Asold
- Botwood Nicholas A.j.sold
- Botwood Nicholas A.j.sold
- Goldan Keith A.sold
- Metzger Michael Asold
- Metzger Michael Asold
- Goldan Keith A.sold
- Metzger Michael Asold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.